Arrowhead Pharmaceuticals (MEX:ARWR) Total Stockholders Equity: MXN8,123 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ARWR Arrowhead Pharmaceuticals Inc MEX:ARWR
49 GF Score
Price MXN454.55
GF Value MXN304.61
! 5 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Total Stockholders Equity?

Arrowhead Pharmaceuticals MEX:ARWR 49 Total Stockholders Equity is MXN8,123 Mil as of Jun. 2026. GuruFocus rates MEX:ARWR with a GF Score™ of 49/100 and a GF Value™ of MXN304.61. The stock has 5 warning signs investors should review.

Arrowhead Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2026 was MXN8,123 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Arrowhead Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 was MXN57.55. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Arrowhead Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 was 2.11.

Arrowhead Pharmaceuticals  (MEX:ARWR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Arrowhead Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(8123.016-0)/141.135
=57.55

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Arrowhead Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(790.824 + 16373.636) / 8123.016
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Total Stockholders Equity Related Terms

Arrowhead Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Total Stockholders Equity Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,406.20 8,016.23 4,726.50 3,651.45 8,549.35

Arrowhead Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,834.74 8,549.35 10,234.84 11,071.66 8,123.02
MEX:ARWR
49GF Score
Arrowhead Pharmaceuticals Inc MEX:ARWR
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of MXN8,123 Mil mean?
Arrowhead Pharmaceuticals (MEX:ARWR) has a Total Stockholders Equity of MXN8,123 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Total Stockholders Equity too high?
Arrowhead Pharmaceuticals' current Total Stockholders Equity is MXN8,123 Mil. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Total Stockholders Equity compare to AXSM and MDGL?
Arrowhead Pharmaceuticals' Total Stockholders Equity of MXN8,123 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Total Stockholders Equity is MXN8,123 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Arrowhead Pharmaceuticals (MEX:ARWR) has a current Total Stockholders Equity of MXN8,123 Mil. The stock's GF Value™ is MXN304.61, compared to a current price of MXN454.55 — trading 49.2% above its estimated fair value. The current Total Stockholders Equity is MXN8,123 Mil. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (MEX:ARWR), the current Total Stockholders Equity is MXN8,123 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (MEX:ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of MXN454.55 is trading 49.2% above its estimated GF Value™ of MXN304.61.

Key valuation signals for MEX:ARWR:

  • Total Stockholders Equity: MXN8,123 Mil
  • GF Value™: MXN304.61 vs. price of MXN454.55 (49.2% above fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the MEX:ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for MEX:ARWR

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN454.55
Price
MXN304.61
GF Value